Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Impact of prior B-cell-directed immunotherapy on the outcome of CD19 CAR T-cell therapy in aggressive B-cell lymphoma - an analysis of the EBMT and the GoCART coalition

Jan Christian Schroeder, Christophe Peczynski, Philipp Berning et al. Nov 03, 2025 pp. 1937-1937 10.1182/blood-2025-1937

Abstract Introduction: Treatment outcomes of diffuse large B-cell lymphoma (DLBCL) and related large B-cell lymphoma (LB...

Real-world safety profile of PD-1 inhibitors in Epstein–Barr Virus–Associated lymphoproliferative disorders: A retrospective analysis from west China hospital

Yang Dai, Pengpeng Liu, Yu Wu et al. Nov 03, 2025 pp. 3008-3008 10.1182/blood-2025-3008

Abstract Background PD-1 inhibitors are increasingly utilized beyond oncology, including in Epstein-Barr virus–associated hemophagocytic lym...

Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry

Vivian Li, Rita Yim, Paul Lee et al. Nov 03, 2025 pp. 2041-2041 10.1182/blood-2025-2041

Abstract Background Large multicenter analysis of myeloproliferative neoplasms (MPNs) has not been conducted in Asia. Ai...

Golidocitinib combined with CHOP in treatment-Naïve monomorphic epitheliotropic intestinal T-cell lymphoma: Preliminary results from A phase 2 multicenter, single-arm goal study

Yu-Ran Qiu, Ming-Ci Cai, Wenyu Li et al. Nov 03, 2025 pp. 3649-3649 10.1182/blood-2025-3649

Abstract Background Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare and highly aggressive subtype of peripheral T-ce...

Efficacy and safety of brentuximab vedotin versus standard therapy for cutaneous T-cell lymphoma: A systematic review and meta-analysis

Ubaid Ahmed, Dua Azim, Jalib Ahmed et al. Nov 03, 2025 pp. 7173-7173 10.1182/blood-2025-7173

Abstract Introduction: Cutaneous T-cell lymphoma (CTCL) is an uncommon form of non-Hodgkin lymphoma. It is often untreatable, particularly a...

Efficacy, safety, and T-cell population dynamics of glofitamab monotherapy in relapsed/refractory B-cell lymphoma

Xin Li, Rui Cui, Jia Wang et al. Nov 03, 2025 pp. 7266-7266 10.1182/blood-2025-7266

Abstract Purpose Patients with relapsed/refractory (R/R) B-cell lymphoma (BCL) have a poor prognosis. We evaluated the efficacy, adverse eve...

Hemorrhage and thrombosis in adult patients with acute lymphoblastic leukemia: A comparative analysis between conventional vs pediatric-inspired induction regimens

Raquel Martinez, Francisco Ramirez Vargas, Maria Ana Robles Rodriguez et al. Nov 03, 2025 pp. 5113-5113 10.1182/blood-2025-5113

Abstract Introduction: Acute lymphoblastic leukemia (ALL) in adults poses unique challenges, particularly during induction therapy. Differen...

Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD anderson symptom inventory (MDASI-BMT)

Portia Smallbone, Jessica Medford, Clark Andersen et al. Nov 03, 2025 pp. 6058-6058 10.1182/blood-2025-6058

Abstract Background: Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for many hematologic malignancies, yet surviv...

Sickle cell disease in the global south: Mapping the unmet burden using global burden of disease DALY estimates and its relevance to United States hematologists

Sweta Sahu, Sravani Bhavanam, Salma Younas et al. Nov 03, 2025 pp. 2601-2601 10.1182/blood-2025-2601

Abstract Sickle cell disease (SCD) affects approximately 7.74 million people globally as of 2021, with nearly 80% residing in sub-Saharan Af...

Oncodif: An auditable AI framework for automated genomic curation and natural-language clinical querying in hematologic malignancies

Mujahid Quidwai, Santiago Thibaud, Sundar Jagannath et al. Nov 03, 2025 pp. 2646-2646 10.1182/blood-2025-2646

Abstract Background Precision treatment in hematologic malignancies relies on rapid, accurate interpretation of tumor ge...

Survival outcomes and treatment patterns in primary and secondary plasma cell leukemia: A multicenter retrospective cohort study

Chenyun Wang, Jinuo Wang, Jiahe Li et al. Nov 03, 2025 pp. 4023-4023 10.1182/blood-2025-4023

Abstract Background: Plasma Cell Leukemia (PCL) is a rare and highly aggressive plasma cell disorder, typically categorized into primary Plas...

Long-term follow-up of venetoclax therapy in AL amyloidosis

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch et al. Nov 03, 2025 pp. 7497-7497 10.1182/blood-2025-7497

Abstract Background: The t(11;14) translocation occurs in 50–60% of patients with systemic AL amyloidosis. Venetoclax, an oral BCL-2 inhibit...

CD19 CAR T cell therapy is an effective strategy for first CNS relapse in pediatric b ALL

Amanda DiNofia, Regina Myers, Yimei Li et al. Nov 03, 2025 pp. 648-648 10.1182/blood-2025-648

Abstract Introduction: The 4-year disease-free survival (DFS) of children with first isolated central nervous system (iCNS) relapse treated...

IVIG prevents infections without affecting mortality in DLBCL patients treated with CAR T-cell or bispecific antibody therapy: A real-world propensity-matched study

Nehemias Guevara, Syeda Ashna Fatima Kamal, Nisheem Pokharel et al. Nov 03, 2025 pp. 1886-1886 10.1182/blood-2025-1886

Abstract Background Chimeric antigen receptor T-cell (CAR T) therapy and bispecific antibodies (BSAB) have transformed the treatment of rela...

CRLF2 expression and MRD kinetics outcomes across the age spectrum in Mexican patients with acute lymphoblastic leukemia: Prevalence and association with post-induction measurable residual disease

Marisa Frausto, Anna Rodriguez-Zuñiga, Carlos de la Cruz-de la Cruz et al. Nov 03, 2025 pp. 5114-5114 10.1182/blood-2025-5114

Abstract Introduction CRLF2 gene rearrangements are the most common genetic alteration in Philadelphia chromosome-like (...

A multi-institutional machine-learning score that predicts bacteremia and gram class at blood-culture initiation

Seongman Bae, Se Yoon Park, Myung-Soo Kim et al. Nov 03, 2025 pp. 4363-4363 10.1182/blood-2025-4363

Abstract Bacteremia is a clinically significant condition due to its potential to rapidly progress to sepsis, a life-threatening complicatio...

Impact of induction response and co-mutations on transplant outcomes in AML with myelodysplasia-related gene mutations: A multicenter retrospective study

Xing Chen, Ruoxuan Zhang, Liang Huang et al. Nov 03, 2025 pp. 3394-3394 10.1182/blood-2025-3394

Abstract Background: Acute myeloid leukemia (AML) is a genetically heterogeneous hematological malignancy. Risk stratification in AML is prim...

Dynamic machine Learning–Based prediction of major bleeding in patients receiving anticoagulant therapy: A multi-center study

Ron Likvornik, Lior Rokach, Noam Benyamini et al. Nov 03, 2025 pp. 314-314 10.1182/blood-2025-314

Abstract Background: Oral anticoagulants are increasingly prescribed for atrial fibrillation, venous thromboembolism (VTE), arterial thrombo...

Temporal assessment of phenotype and receptor profile of in vitro expanded healthy natural killer cells using irradiated feeder cells

Fareena Bilwani, Syed Muhammad Areeb Ahmed, Mohammad Khurshid Nov 03, 2025 pp. 7695-7695 10.1182/blood-2025-7695

Abstract Allogeneic natural killer (NK) cell therapy is an emerging approach in treating hematological malignancies. NK cells recognize tumo...

Analysis of cardiovascular risk factors in a cohort of patients with ITP in a tertiary care center

Irene Castaño Caballero, Gala Cabirta Touzon, Manuel Rodriguez Lopez et al. Nov 03, 2025 pp. 6583-6583 10.1182/blood-2025-6583

Abstract INTRODUCTION There is a higher risk of thrombosis in ITP compared to general population, but little is known ab...

Gut microbiota recovery via butyrate supplementation prevents acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Seug Yun Yoon, Sun Young Jeong, Min-Young Lee et al. Nov 03, 2025 pp. 4226-4226 10.1182/blood-2025-4226

Abstract Background Acute graft-versus-host disease (aGVHD) is a significant cause of morbidity and mortality in patients undergoing allogen...

Targeted long-read sequencing with adaptive sampling in multiple myeloma: A pilot study toward a unified diagnostic platform

Beñat Ariceta, Paula Aguirre-Ruiz, Andrea Castro et al. Nov 03, 2025 pp. 6121-6121 10.1182/blood-2025-6121

Abstract INTRODUCTION Multiple Myeloma (MM) is a genetically complex blood cancer marked by diverse mutations, structural rearrangements, an...

First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation

Amandeep Salhotra, Jamie Wagner, Dongyun Yang et al. Nov 03, 2025 pp. 276-276 10.1182/blood-2025-276

Abstract Chronic graft-versus-host disease (cGVHD) remains the leading cause of late nonrelapse mortality and morbidities affecting quality...

Lipid deregulation impacts hematopoietic stem cell functions during aging

Devyani Sharma, Juying Xu, Angelo D'Alessandro et al. Nov 03, 2025 pp. 975-975 10.1182/blood-2025-975

Abstract Hematopoietic Stem Cells (HSC) have high regenerative potential to sustain the production of blood throughout life. This property a...

Cardioembolic stroke in children and young adults: Comprehensive management and risk of hemorrhagic transformation-a single institutional experience

Robert Burks, Amanda Sankar, Vilmarie Rodriguez et al. Nov 03, 2025 pp. 4915-4915 10.1182/blood-2025-4915

Abstract Background: Cardio-Embolic stroke affects up to 8 percent of children with congenital heart disease. Pediatric stroke guidelines re...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page